Menu
Back to Journals » OncoTargets and Therapy » Volume 7
Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
Authors Wang F, Wang F, Bai L, Xu R
Received 13 August 2013
Accepted for publication 4 October 2013
Published 2 April 2014 Volume 2014:7 Pages 501—511
DOI https://doi.org/10.2147/OTT.S38843
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Feng Wang,* Feng-Hua Wang,* Long Bai, Rui-Hua Xu
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
*These authors contributed equally to this work
Abstract: The China Food and Drug Administration approved the use of capecitabine in patients with metastatic colorectal cancer (mCRC) in 2004. This paper reviews the available information of capecitabine in Chinese patients with mCRC, focusing on its effectiveness and safety against mCRC. Identification of all eligible studies was made by searching the PubMed and Wanfang database from 2000 to 2013. Published data examining various aspects of clinical response and tolerability with capecitabine alone or in combination with other chemotherapeutic or biological agents for first- and second-line mCRC were examined. Capecitabine and its combination displayed high efficacy in Chinese patients with mCRC. Toxicities are generally manageable, and elderly patients can tolerate capecitabine well.
Keywords: capecitabine, metastatic colorectal cancer, Chinese
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.